Thermo to Acquire Sanofi’s Sterile Manufacturing Site, Expanding Strategic Partnership
The site in Ridgefield, N.J., will provide Thermo with additional U.S. drug product manufacturing capacity and will allow the company to meet the growing demand from pharma and biotech customers for U.S. drug product manufacturing.
Thermo Fisher Scientific has announced its plans to expand its strategic partnership with Sanofi by acquiring the biopharma’s sterile manufacturing site in Ridgefield, N.J. (1). Through this site acquisition, Thermo is seeking to increase its U.S. based manufacturing capacity, allowing it to meet increased demand for critical medicines.
“Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, Chairman, President, and Chief Executive Officer of Thermo Fisher, in a company press release (1). “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.”
While Thermo will acquire the Ridgefield site, under the terms of the agreement, it will continue to manufacture a portfolio of therapies for Sanofi. Additionally, Thermo will expand the use of the site so that it can meet the increasing demand for U.S. manufacturing capacity from pharma and biotech customers.
"This expansion of our long-term partnership with Thermo Fisher will help ensure a continued supply of high-quality Sanofi products, maintaining our commitment to American manufacturing and supporting our customers and patients in the U.S., while enabling the future development and growth of the site," added Brendan O’Callaghan, Global Head of Manufacturing & Supply, Sanofi, in the press release (1).
Earlier in the year, Thermo revealed its plans to invest an additional USD 2 billion into U.S. manufacturing and R&D innovation (2). The planned investment comprises USD 1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations, along with USD 500 million for high-impact innovation R&D.
“Thermo Fisher’s commitment to U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation. Thermo Fisher is proud to serve as a growth engine for the American economy,” explained Casper, in a press release about the investment plans (2). “By expanding our U.S. operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come.”
However, the financial terms of Thermo’s latest deal with Sanofi have not been disclosed, but the transaction is expected to be closed in the second half of 2025, subject to customary closing conditions. Once the transaction is complete, the Ridgefield facility will form part of Thermo’s pharma services business within the Laboratory Products and Biopharma Services segment (1).
References
Thermo Fisher Scientific. Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing. Press Release, July 16, 2025.
Thermo Fisher Scientific. Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers’ Manufacturing. Press Release, April 24, 2025.